Lodestar Investment Counsel Has Lifted Amgen (AMGN) Position By $421,090; KONAMI HLDGS ORDINARY SHARES (KNAMF) Shorts Raised By 46.01%

June 21, 2018 - By Louis Casey

Amgen Inc. (NASDAQ:AMGN) Logo

Lodestar Investment Counsel Llc increased Amgen (AMGN) stake by 2.48% reported in 2018Q1 SEC filing. Lodestar Investment Counsel Llc acquired 2,477 shares as Amgen (AMGN)’s stock declined 5.44%. The Lodestar Investment Counsel Llc holds 102,335 shares with $17.45M value, up from 99,858 last quarter. Amgen now has $122.37 billion valuation. The stock decreased 0.85% or $1.58 during the last trading session, reaching $184.93. About 432,278 shares traded. Amgen Inc. (NASDAQ:AMGN) has risen 14.68% since June 21, 2017 and is uptrending. It has outperformed by 2.11% the S&P500. Some Historical AMGN News: 23/03/2018 – Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of; 16/05/2018 – AMGEN GETS EC APPROVAL FOR REPATHA® (EVOLOCUMAB) TO PREVENT HEA; 06/03/2018 – Amgen Preliminary Proration Factor for Tender Offer Is Approximately 95.9%; 27/04/2018 – Bolder BioTechnology Announces Positive Results from Phase 1 Clinical Trial of BBT-015, a Long-Acting G-CSF Analog, in Healthy; 05/04/2018 – AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes With Samsung Bioepis; 30/04/2018 – Amgen: KYPROLIS Multiple Myeloma Treatment Shows Overall Survival in Two Phase 3 Studies; 21/03/2018 – Adweek: Pharma Giant Amgen Sends Its Estimated $350 Million U.S. Media Business to Hearts & Science; 01/05/2018 – Regeneron Pharma: Agreement Provides Praluent at Lower Net Price and Enables Streamlined Patient Access Based on Physician Attestatio; 17/05/2018 – Amgen: FDA Approves Aimovig, a Novel Treatment Developed Specifically for Migraine Prevention; 17/05/2018 – BeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the Prevention of Che

KONAMI HLDGS CORP ORDINARY SHARES (OTCMKTS:KNAMF) had an increase of 46.01% in short interest. KNAMF’s SI was 1.14M shares in June as released by FINRA. Its up 46.01% from 777,400 shares previously. With 100 avg volume, 11351 days are for KONAMI HLDGS CORP ORDINARY SHARES (OTCMKTS:KNAMF)’s short sellers to cover KNAMF’s short positions. It closed at $53.0207 lastly. It is down 0.00% since June 21, 2017 and is . It has underperformed by 12.57% the S&P500.

Since January 16, 2018, it had 0 insider buys, and 6 insider sales for $1.65 million activity. 1,525 shares were sold by Harper Sean E, worth $289,369.

Investors sentiment decreased to 0.88 in Q1 2018. Its down 0.34, from 1.22 in 2017Q4. It fall, as 67 investors sold AMGN shares while 557 reduced holdings. 114 funds opened positions while 435 raised stakes. 502.72 million shares or 8.88% less from 551.71 million shares in 2017Q4 were reported. Fund Evaluation Gp Lc has 0.18% invested in Amgen Inc. (NASDAQ:AMGN). Cibc Markets invested in 163,910 shares or 0.3% of the stock. Ima Wealth Inc invested 0.84% of its portfolio in Amgen Inc. (NASDAQ:AMGN). Amf Pensionsforsakring Ab reported 674,539 shares. 62,499 are held by Bridgewater Limited Partnership. Bancorp Of Nova Scotia reported 129,707 shares. Carlton Hofferkamp Jenks Wealth Ltd Liability Co reported 4,211 shares stake. Compton Cap Mngmt Ri stated it has 8,718 shares. Andra Ap has invested 0.25% in Amgen Inc. (NASDAQ:AMGN). Allsquare Wealth Management Ltd Com owns 357 shares. Private Capital Advsrs reported 36,375 shares or 2.07% of all its holdings. Washington Trust has invested 0.52% in Amgen Inc. (NASDAQ:AMGN). Reilly Financial Advsrs Limited Liability Corporation stated it has 0.06% in Amgen Inc. (NASDAQ:AMGN). Advisory Serv Ltd Liability Com reported 18,574 shares stake. 526,251 are held by Stifel Financial Corp.

Lodestar Investment Counsel Llc decreased Microsoft Corporation (NASDAQ:MSFT) stake by 10,887 shares to 423,072 valued at $38.61 million in 2018Q1. It also reduced General Electric (NYSE:GE) stake by 236,845 shares and now owns 71,539 shares. Starwood Property Trust (NYSE:STWD) was reduced too.

Among 25 analysts covering Amgen Inc. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 14 Hold. Therefore 44% are positive. Amgen Inc. had 89 analyst reports since August 3, 2015 according to SRatingsIntel. Oppenheimer maintained the shares of AMGN in report on Wednesday, August 16 with “Buy” rating. The stock has “Market Perform” rating by BMO Capital Markets on Wednesday, July 26. BMO Capital Markets maintained the shares of AMGN in report on Friday, October 20 with “Hold” rating. As per Tuesday, October 3, the company rating was maintained by Cowen & Co. The rating was maintained by Jefferies with “Buy” on Thursday, September 28. On Monday, February 8 the stock rating was maintained by Argus Research with “Buy”. On Friday, July 21 the stock rating was maintained by BMO Capital Markets with “Buy”. The stock has “Buy” rating by Oppenheimer on Wednesday, August 23. Argus Research downgraded Amgen Inc. (NASDAQ:AMGN) on Wednesday, November 1 to “Hold” rating. The stock has “Overweight” rating by Morgan Stanley on Friday, October 6.

Amgen Inc. (NASDAQ:AMGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.